Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) – Pipeline Review, H1 2018’, provides in depth analysis on Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Cardiovascular and Respiratory under development targeting Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1)

– The report reviews Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects

– The report assesses Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

ADC Therapeutics SA

Astellas Pharma Inc

BerGenBio ASA

Betta Pharmaceuticals Co Ltd

Celldex Therapeutics Inc

Daiichi Sankyo Co Ltd

Exelixis Inc

F1 Oncology Inc

Ignyta Inc

Incyte Corp

Les Laboratoires Servier SAS

Mirati Therapeutics Inc

Ono Pharmaceutical Co Ltd

Oribase Pharma

Qurient Co Ltd

Rigel Pharmaceuticals Inc

SignalChem Lifesciences Corp

Takeda Pharmaceutical Co Ltd

Tolero Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC

2.7.10.1) - Overview

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC

2.7.10.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC

2.7.10.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC

2.7.10.1) - Companies Involved in Therapeutics Development

ADC Therapeutics SA

Astellas Pharma Inc

BerGenBio ASA

Betta Pharmaceuticals Co Ltd

Celldex Therapeutics Inc

Daiichi Sankyo Co Ltd

Exelixis Inc

F1 Oncology Inc

Ignyta Inc

Incyte Corp

Les Laboratoires Servier SAS

Mirati Therapeutics Inc

Ono Pharmaceutical Co Ltd

Oribase Pharma

Qurient Co Ltd

Rigel Pharmaceuticals Inc

SignalChem Lifesciences Corp

Takeda Pharmaceutical Co Ltd

Tolero Pharmaceuticals Inc

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC

2.7.10.1) - Drug Profiles

ADCT-601 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibodies to Inhibit AXL, MERTK and TYRO3 for Oncology, Inflammation, Autoimmune Diseases and Infectious Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bemcentinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BGB-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BGB-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BGB-149 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BGB-601 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BPI-9016 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cabozantinib s-malate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCT-30138 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CT-053 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CT-413 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DS-1205 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Inhibit Axl Tyrosine kinase for Non-Small Cell Lung Cancer and Thrombosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gilteritinib fumarate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HOPE-777 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INCB-81776 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ONO-7475 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ORY-012 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Q-701 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

R-916562 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RXDX-106 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-49076 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sitravatinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SLC-0211 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit AXL for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TP-0903 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC

2.7.10.1) - Dormant Products

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC

2.7.10.1) - Discontinued Products

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC

2.7.10.1) - Product Development Milestones

Featured News & Press Releases

Apr 26, 2018: Cabozantinib to Be Featured in 15 Presentations at ASCO 2018 Annual Meeting

Apr 23, 2018: Astellas Submits New Drug Applications for Approval of Gilteritinib for the Treatment of FLT3mut+ Relapsed or Refractory Acute Myeloid Leukemia

Apr 18, 2018: BerGenBio: Promising data highlighting selective AXL inhibitor bemcentinib's potential to improve efficacy of checkpoint inhibitors presented at AACR

Apr 13, 2018: Promising pre-clinical data supporting BerGenBios pipeline to be published and presented at upcoming leading conferences

Apr 11, 2018: ADC Therapeutics to Present New Investigational Antibody-Drug Conjugate ADCT-601 at the American Association for Cancer Research (AACR) Annual Meeting

Apr 10, 2018: BerGenBio Completes Recruitment Into First Stage of Phase II NSCLC Trial With Selective AXL Inhibitor Bemcentinib Combined With KEYTRUDA

Mar 28, 2018: Ipsen Announces EMA Validation of Filing of a New Application for Additional Indication for Cabometyx, for patients with previously treated advanced Hepatocellular Carcinoma (HCC)

Mar 23, 2018: Exelixis Partner Ipsen Announces Positive CHMP Opinion for CABOMETYX (cabozantinib) for Previously Untreated Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma

Mar 22, 2018: BerGenBio to present overview of phase II clinical trial portfolio combining bemcentinib with KEYTRUDA at 3rd Annual Immuno-Oncology Summit Europe

Mar 22, 2018: Astellas Receives Orphan Drug Designation from the Japanese MHLW for Gilteritinib

Mar 15, 2018: Exelixis Submits U.S. Supplemental New Drug Application for CABOMETYX (Cabozantinib) for Previously Treated Advanced Hepatocellular Carcinoma

Mar 15, 2018: BerGenBio: Promising data highlighting bemcentinib's potential to improve efficacy of checkpoint inhibitors to be presented at AACR Annual Meeting

Feb 19, 2018: BerGenBio Completes Recruitment Into First Stage of Phase II Breast Cancer Trial With Selective AXL Inhibitor Bemcentinib Combined With KEYTRUDA

Feb 15, 2018: Ipsen's rare medullary thyroid cancer treatment Cometriq (cabozantinib), gets nod from NICE

Feb 13, 2018: Cabozantinib shows significant activity in the first line for differentiated thyroid cancer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..3), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1)

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Products under Development by Companies, H1 2018 (Contd..5), H1 2018

Products under Development by Companies, H1 2018 (Contd..6), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by ADC Therapeutics SA, H1 2018

Pipeline by Astellas Pharma Inc, H1 2018

Pipeline by BerGenBio ASA, H1 2018

Pipeline by Betta Pharmaceuticals Co Ltd, H1 2018

Pipeline by Celldex Therapeutics Inc, H1 2018

Pipeline by Daiichi Sankyo Co Ltd, H1 2018

Pipeline by Exelixis Inc, H1 2018

Pipeline by F1 Oncology Inc, H1 2018

Pipeline by Ignyta Inc, H1 2018

Pipeline by Incyte Corp, H1 2018

Pipeline by Les Laboratoires Servier SAS, H1 2018

Pipeline by Mirati Therapeutics Inc, H1 2018

Pipeline by Ono Pharmaceutical Co Ltd, H1 2018

Pipeline by Oribase Pharma, H1 2018

Pipeline by Qurient Co Ltd, H1 2018

Pipeline by Rigel Pharmaceuticals Inc, H1 2018

Pipeline by SignalChem Lifesciences Corp, H1 2018

Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018

Pipeline by Tolero Pharmaceuticals Inc, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

Dormant Products, H1 2018 (Contd..2), H1 2018

Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports